long intergenic non-protein coding RNA 2813Genealiases: []
Q-omics provides the consensus-scored LINC02813 profile across patient tissues and cancer cell-line models. LINC02813 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, LINC02813 is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, LINC02813 RNA expression shows 8,669 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KICH, KIRC, and UVM as cancer lineages where LINC02813 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02813 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02813 survival associations across molecular data types. LINC02813 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02813 RNA expression–survival associations across cancer types. High LINC02813 expression shows unfavorable associations in KICH, UVM, READ, HNSC and ACC, but favorable associations in ESCA. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for LINC02813 RNA expression.
This table summarizes LINC02813 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02813. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02813 shows higher tumor expression in KIRC, COAD, PRAD, LUAD, LUSC and THCA. The KIRC box plot shows higher LINC02813 RNA expression in tumor versus normal tissue (log2 FC = +0.090, t-test p = .004).
This table shows molecular features associated with LINC02813 in patient tissues and cancer cell lines. In patient samples, LINC02813 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
